Taken together, our study elucidates the molecular mechanism underlying CDK9 inhibitor-induced SL in APC-deficient cells, providing novel insights into CRC pathogenesis and the development of innovative treatment strategies. The gene discussed is CDK9; the disease is colorectal carcinoma.